# Real-World Evaluation of Patient Characteristics and Treatment Patterns Among Patients With CML-CP Treated With Asciminib

> **NCT06516029** · — · COMPLETED · sponsor: **Novartis** · enrollment: 111 (actual)

## Conditions studied

- Chronic Myeloid Leukemia, Chronic Phase

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06516029
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-04-21
- **Primary completion:** 2023-10-02
- **Final completion:** 2023-10-02
- **Target enrollment:** 111 (ACTUAL)
- **Last updated:** 2024-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06516029

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06516029, "Real-World Evaluation of Patient Characteristics and Treatment Patterns Among Patients With CML-CP Treated With Asciminib". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06516029. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*